| Literature DB >> 24066945 |
Mourad Assidi1, François J Richard, Marc-André Sirard.
Abstract
The use of gonadotropins to trigger oocyte maturation both in vivo and in vitro has provided precious and powerful knowledge that has significantly increased our understanding of the ovarian function. Moreover, the efficacy of most assisted reproductive technologies (ART) used in both humans and livestock species relies on gonadotropin input, mainly FSH and LH. Despite the significant progress achieved and the huge impact of gonadotropins, the exact molecular pathways of the two pituitary hormones, FSH and LH, still remain poorly understood. Moreover, these pathways may not be the same when moving from the in vivo to the in vitro context. This misunderstanding of the intricate synergy between these two hormones leads to a lack of consensus about their use mainly in vitro or in ovulation induction schedules in vivo. In order to optimize their use, additional work is thus required with a special focus on comparing the in vitro versus the in vivo effects. In this context, this overview will briefly summarize the downstream gene expression pathways induced by both FSH in vitro and LH in vivo in the cumulus compartment. Based on recent microarray comparative analysis, we are reporting that in vitro FSH stimulation on cumulus cells appears to achieve at least part of the gene expression activity after in vivo LH stimulation. We are then proposing that the in vitro FSH-response of cumulus cells have similitudes with the in vivo LH-response.Entities:
Year: 2013 PMID: 24066945 PMCID: PMC3852229 DOI: 10.1186/1757-2215-6-68
Source DB: PubMed Journal: J Ovarian Res ISSN: 1757-2215 Impact factor: 4.234
Figure 1Model of gonadotropin-mediated induction of oocyte competence in vivo versus in vitro: In addition to its own effects, could FSH in vitro substitute for some of the effects of LH? FSH: follicle stimulating hormone; LH: luteinizing hormone.
Common overexpressed genes in bovine CCs around the GVBD between FSH in vitro versus LH in vivo
| 1 | ATP1B4 | Bos taurus ATPase, (Na+)/K + transporting, beta 4 polypeptide | NM_001101919 |
| 2 | ATP6V1C1 | Bos taurus ATPase, H + transporting, lysosomal 42kDa, V1 subunit C1 | NM_176676 |
| 3 | BAMBI | Bos taurus BMP and activin membrane-bound inhibitor homolog | NM_001046309 |
| 4 | HSPA8 | Bos taurus heat shock 70 kDa protein 8 | NM_174345 |
| 5 | INHBA | Bos taurus inhibin, beta A | NM_174363 |
| 6 | PAPD1 | Bos taurus PAP associated domain containing 1 | BC104501 |
| 7 | PSMA2 | Bos taurus proteasome (prosome, macropain) subunit, alpha type, 2 | BC102206 |
| 8 | RHOA | Bos taurus ras homolog gene family, member A | NM_176645 |
| 9 | RPL3 | Bos taurus ribosomal protein L3 | BT021012 |
| 10 | SELK | Bos taurus similar to selenoprotein K | BC108150 |
| 11 | SLC25A5 | Bos taurus solute carrier family 25 member 5 | BC102950 |
| 12 | TNFAIP6 | Bos taurus tumor necrosis factor, alpha-induced protein 6 | NM_001007813 |
| 13 | UBA6 | Bos taurus ubiquitin-like modifier activating enzyme 6 | NM_001083438 |
| 14 | CHSY1 | Homo sapiens carbohydrate (chondroitin) synthase 1 | NM_014918 |
| 15 | EREG | Homo sapiens epiregulin | NM_001432 |
| 16 | FOXO3A | Homo sapiens forkhead box O3 (FOXO3), transcript variant 2, mRNA | NM_201559 |
| 17 | PGR | Bos taurus progesterone receptor | NC_007313.4 |
| 18 | NEAT1 | Homo sapiens nuclear enriched abundant transcript 1 | EF177379 |
| 19 | SGMS2 | Homo sapiens sphingomyelin synthase 2 (SGMS2), transcript variant | NM_001136258 |
| 20 | AGPAT9 | PREDICTED: Bos taurus similar to 1-acyl-sn-glycerol-3-phosphate O-acyltransferase 9 | XM_597964 |
| 21 | RBMX | PREDICTED: Bos taurus similar to Heterogeneous nuclear ribonucleoprotein G | XM_875611 |
| 22 | SLC39A8 | PREDICTED: Bos taurus similar to Solute carrier family 39 (zinc transporter), member 8 | XM_584935 |
Real-time PCR validation of overexpression following FSH in vitro(*) or LH in vivo (); α = 0.05%.
Figure 2Common genes overexpressed by FSH in vitro versus LH in vivo in bovine CCs around the GVBD, as revealed by microarray.FSH: follicle stimulating hormone; LH: luteinizing hormone.
Figure 3A summary of a gene network including common gene candidates induced by both FSH in vitro and LH/hCG in vivo as revealed by the IPA software. FSH: follicle-stimulating hormone; LH/hCG: luteinizing hormone/human chorionic gonadotropin; EREG: epiregulin; TNFAIP6: tumor necrosis factor, alpha-induced protein 6; INHBA: inhibin, beta A; BAMBI: BMP and activin membrane-bound inhibitor homolog (Xenopus laevis); FOXO3: forkhead box O3; RHOA: ras homolog gene family, member A; TGFB1: transforming growth factor, beta 1; PTX3: pentraxin-related gene, rapidly induced by IL-1 beta; BTC: betacellulin; ITIH3: inter-alpha (globulin) inhibitor H3; SLC39A8: solute carrier family 39 (zinc transporter), member 8; VEGF family: vascular endothelial growth factor; PLCL1: phospholipase C-like 1; SGMS2: sphingomyelin synthase 2; AGPAT9: 1-acylglycerol-3-phosphate O-acyltransferase 9; EIF4EBP1: eukaryotic translation initiation factor 4E binding protein 1.